Bladder Cancer
Conditions
Keywords
S/P Transuretral resection of bladder tumor, Recurrent tumor after BCG Treatment
Brief summary
PURPOSE: We determined whether Synergo therapy- intravesical chemotherapy instillation combined with hyperthermia instillation is associated with elevated prostate specific antigen (PSA). MATERIALS AND METHODS: We will treat 25 consecutive patients with bladder cancer with a 6-week course of Synergo therapy, followed by cystoscopy at 6 weeks. Blood samples for PSA determination will obtain before each synergo therapy application and at cystoscopy with each patient also serving as a control. Evaluating changes in PSA level in patients undergoing treatment with Synergo delivered local hyperthermia combined with intravesical instillation of Mitomycin C for adjuvant treatment or pt. with recurrent tu of bladder post TURT with BCGtreatment.
Interventions
DEVICESYNERGO
DEVICESYNERGO-intravesical chemotherapy instillation combined with hyperthermia
Sponsors
HaEmek Medical Center, Israel
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
30 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Recurrent transitional cell carcinoma of urinary bladder post endoscopic resection * PSA Prior synergo therapy application\<10 * Normal rectal examination * Patients willing to sign informed consent according
Exclusion criteria
* History of prostate cancer * Previous history of TCC stage T2 or higher * Invasive tu of bladder * Prior pelvic radiotherapy or systemic chemotherapy * Active prostatitis * Active tuberculosis
Countries
Israel
Contacts
Primary Contactdoron perez, M.D.
Outcome results
None listed